Develops immuno-oncology therapies for cancer treatment, focusing on novel antibodies and combination therapies.
Leap Therapeutics, Inc. is a pioneering biopharmaceutical company dedicated to acquiring and advancing innovative cancer therapies. At the forefront of its clinical portfolio is DKN-01, a monoclonal antibody designed to inhibit Dickkopf-related protein 1 (DKK1). This promising therapy is currently undergoing multiple clinical trials targeting a spectrum of cancers including esophagogastric, hepatobiliary, gynecologic, and prostate cancers.
In strategic collaboration with BeiGene, Ltd., Leap Therapeutics has entered into an option and license agreement to develop and commercialize DKN-01 across Asia (excluding Japan), Australia, and New Zealand. This partnership underscores Leap Therapeutics' commitment to expanding global access to cutting-edge cancer treatments through collaborative efforts with leading industry players.
Founded in 2011 and headquartered in Cambridge, Massachusetts, Leap Therapeutics, Inc. was formerly known as HealthCare Pharmaceuticals, Inc. The company rebranded to Leap Therapeutics to reflect its renewed focus and commitment to advancing novel therapies that address critical unmet needs in oncology. With a robust pipeline and strategic partnerships, Leap Therapeutics continues to drive innovation in cancer treatment, aiming to improve outcomes and quality of life for patients worldwide.